How many insider trades does FilingIQ track for CRVO?

FilingIQ tracks 42 Form 4 insider transactions for CRVO (CervoMed Inc.), covering filings from Aug 31, 2023 onwards. 8 of those were filed in the last 90 days.

Are CRVO insiders net buyers or net sellers?

Across the full Form 4 history for CRVO, 20 transactions (48%) were open-market purchases and 1 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CRVO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CRVO in?

CervoMed Inc. (CRVO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $43.49M.

CRVO insider trading

Healthcare

CervoMed Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

48% / 2%

Market cap

$43.49M

About CervoMed Inc.

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Company website: www.cervomed.com

CRVO insider activity at a glance

FilingIQ has scored 42 insider transactions for CRVO since Aug 31, 2023. The most recent filing in our index is dated Jun 8, 2026.

Across the full history, 20 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CRVO insider trades is 54.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CRVO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,223

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 152

Guardant Health, Inc.

KalVista Pharmaceuticals, Inc.

KNSA 129

Kiniksa Pharmaceuticals International, plc

Frequently asked

How many insider trades does FilingIQ track for CRVO?: FilingIQ tracks 42 Form 4 insider transactions for CRVO (CervoMed Inc.), covering filings from Aug 31, 2023 onwards. 8 of those were filed in the last 90 days.
Are CRVO insiders net buyers or net sellers?: Across the full Form 4 history for CRVO, 20 transactions (48%) were open-market purchases and 1 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CRVO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CRVO in?: CervoMed Inc. (CRVO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $43.49M.

Methodology & sources

Every CRVO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.